Neurocrine Biosciences, Inc. (NBIX) Expected to Announce Earnings of -$0.30 Per Share
Equities analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to post earnings of ($0.30) per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Neurocrine Biosciences’ earnings, with estimates ranging from ($0.46) to ($0.16). Neurocrine Biosciences posted earnings of ($0.90) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 66.7%. The firm is scheduled to announce its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to $0.37. For the next year, analysts anticipate that the business will report earnings of $1.85 per share, with EPS estimates ranging from $0.67 to $2.53. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The business had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the previous year, the firm posted ($0.51) EPS.
Neurocrine Biosciences (NBIX) traded down $1.15 during midday trading on Friday, reaching $84.27. The company’s stock had a trading volume of 554,049 shares, compared to its average volume of 972,976. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99. The firm has a market cap of $7,460.00, a P/E ratio of -51.70 and a beta of 0.26. Neurocrine Biosciences has a 12-month low of $39.21 and a 12-month high of $91.82.
In related news, insider Darin Lippoldt sold 6,279 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $75.04, for a total value of $471,176.16. Following the transaction, the insider now owns 19,436 shares in the company, valued at $1,458,477.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William H. Rastetter sold 9,500 shares of the stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $90.00, for a total value of $855,000.00. Following the completion of the transaction, the director now owns 34,250 shares in the company, valued at approximately $3,082,500. The disclosure for this sale can be found here. Insiders sold 342,950 shares of company stock worth $27,037,226 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in NBIX. The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. State Board of Administration of Florida Retirement System boosted its position in Neurocrine Biosciences by 0.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after purchasing an additional 810 shares during the period. Amalgamated Bank boosted its position in Neurocrine Biosciences by 5.7% during the fourth quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock worth $1,357,000 after purchasing an additional 947 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Neurocrine Biosciences by 25.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock worth $458,000 after purchasing an additional 1,200 shares during the period. Finally, Grandfield & Dodd LLC boosted its position in Neurocrine Biosciences by 24.1% during the third quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock worth $466,000 after purchasing an additional 1,480 shares during the period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.